VICTORVILLE — A new prostate cancer scan that is extending the lives of patients is now available in the High Desert. Axumin is a recently FDA-approved imaging agent that detects recurrent cancer ...

BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced results from an investigational clinical trial ...

In patients with PSA levels ≤ 1.78 ng/mL, 15 of 25 had a positive scan, with 11 confirmed as positive by histology; 71 of 74 patients with PSA levels > 1.78 ng/mL had a positive scan, of which 58 were ...

Please provide your email address to receive an email when new articles are posted on . The FDA today approved Axumin, an injectable radioactive diagnostic agent used to detect recurrent prostate ...

The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected ...

A new effective PET/CT scan for prostate cancer patients can detect the location and extent of cancer that has recurred after initial treatment. Prostate PET/CT scans can detect cancer earlier than ...

The US Food and Drug Administration (FDA) approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected ...

A phase 3 study from molecular imaging firm Blue Earth Diagnostics found that its Axumin contrast agent for PET scans could assist in the diagnosis of patients with glioma. Axumin, consisting of the ...

Comments on this technology were invited from clinical experts working in the field. The comments received are individual opinions and do not represent NICE's view. Two out of 6 specialist ...

Patients must be routinely checked for prostate cancer recurrence after prostate cancer surgery. Statistically, prostate cancer has a higher chance of recurrence. Patients should undergo a routine ...

A literature search was carried out for this briefing in accordance with the interim process and methods statement. This briefing includes the most relevant or best available published evidence ...